Pietropaolo V, Prezioso C, Moens U. Role of virus‐induced host cell epigenetic changes in cancer. Int J Mol Sci. 2021;22:1–51.

Article  Google Scholar 

Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, et al. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100. Blood. 2020;136:871–84.

Article  PubMed  Google Scholar 

Herr W, Perlmutter AP, Gilbert W. Monoclonal AKR/J thymic leukemias contain multiple J(H) immunoglobulin gene rearrangements. Proc Natl Acad Sci USA. 1983;80:7433–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, et al. Silylation of deoxynucleotide analog yields an orally available drug with antileukemia effects. Mol Cancer Ther. 2021;20:1412–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reicin A, Yang JQ, Marcu KB, Fleissner E, Koehne CF, O’Donnell PV. Deregulation of the c-Tr oncogene in virus-induced thymic lymphomas of AKR/J mice. Mol Cell Biol. 1986;6:4088–92.

CAS  PubMed  PubMed Central  Google Scholar 

Hattori N, Sako M, Kimura K, Iida N, Takeshima H, Nakata Y, et al. Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Clin Epigenetics. 2019;11:1–12.

Article  CAS  Google Scholar 

Lisanti S, Omar WAW, Tomaszewski B, De Prins S, Jacobs G, Koppen G, et al. Comparison of methods for quantification of global DNA methylation in human cells and tissues. PLoS ONE. 2013;8:e79044.

Article  PubMed  PubMed Central  Google Scholar 

Yoshida-Sakai N, Watanabe T, Yamamoto Y, Ureshino H, Kamachi K, Kurahashi Y, et al. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism. Int J Cancer. 2022;150:1184–97.

Article  CAS  PubMed  Google Scholar 

Somasundaram R, Jensen CT, Tingvall-Gustafsson J, Åhsberg J, Okuyama K, Prasad M, et al. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene. Blood. 2021;137:3037–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nasri Nasrabadi P, Martin D, Gharib E, Robichaud GA. The pleiotropy of PAX5 gene products and function. Int J Mol Sci. 2022;23:1–24.

Article  Google Scholar 

Familiades J, Bousquet M, Lafage-Pochitaloff M, Béné MC, Beldjord K, De Vos J, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: A GRAALL study. Leukemia. 2009;23:1989–98.

Article  CAS  PubMed  Google Scholar 

Zhao L, Li S, Gan L, Li C, Qiu Z, Feng Y, et al. Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expression. J Cell Mol Med. 2016;20:842–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stomper J, Rotondo JC, Greve G, Lübbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35:1873–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kimura S, Usuki K, Ichinohe T, Ikezoe T, Kuroda J, Kasahara S, et al. An open-label, multicenter, single-arm, phase I dose escalation study of OP-2100, an orally bioavailable prodrug of decitabine, for patients with relapsed or refractory higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia. Blood. 2023;142:6466.

Article  Google Scholar